|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.36 USD | -1.82% |
|
+3.37% | -3.97% |
| Jul. 10 | Roivant Sciences Ltd. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04:20 PM | |
| Jul. 10 | AI Mania Masks Trade War Risks |  |
Summary: Roivant Sciences Ltd.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Roivant Sciences Ltd.
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses: Roivant Sciences Ltd.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings Chart: Roivant Sciences Ltd.
Source: Surperformance
ESG chart: Roivant Sciences Ltd.
Source: MSCI
| Fundamentals (Composite) | Global Valuation (Composite) | Financial estimates revisions (Composite) | Capi.($) | ||
|---|---|---|---|---|---|
| - | - | 7.72B | |||
| 712B | |||||
| 378B | |||||
| 340B | |||||
| 305B | |||||
| 259B | |||||
| 237B | |||||
| 219B | |||||
| 209B | |||||
| 159B | |||||
| Average | 282.48B | ||||
| Weighted average by Cap. |
Investor (Composite)
-
Trader (Composite)
ESG MSCI
BB
Financials
Revenue growth
EPS growth
Capital Efficiency (Composite)
Net Margin
-
Financial Health (Composite)
-
Valuation
P/E
-
EV/Revenue
EV/EBITDA
-
PBR
-
Dividend Yield
-
Revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
Revenue revisions (1 month)
EPS revisions (1 year)
EPS revisions (4 months)
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (4 months)
Analysts' target price evolution (1 year)
Business Predictability
Surprise rates
Analysts' coverage
Analysts' recommendations divergence
Analysts' Target price divergence
Financial estimates divergence
ESG
Environment
Social
Governance
Controversy
Ethical controversies
Human rights controversies
Tax subsidies controversies
Sharia compliant
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ROIV Stock
- Ratings Roivant Sciences Ltd.
Select your edition
All financial news and data tailored to specific country editions
